Need to demonstrate the economic value of stroke treatments? Discover StrokEnomics!

 

In the context of these past years where the clinical benefit of endovascular thrombectomy has become more and more acknowledged while its long-term cost-effectiveness remains misunderstood, Stryker has been driven to develop our own health economics programs – StrokEnomics – to help our customers make stroke care better.

 

The StrokEnomics center generates the evidence needed to demonstrate the economic value of both innovative acute ischemic and hemorrhagic stroke treatment solutions. Our goal is to ensure that these therapeutic solutions and the procedures during which they are used are properly funded and accessible to all eligible patients.

 

Demonstrating the economic value of next-generation treatments is a mandatory step towards convincing payors – health authorities in charge of reimbursement, hospital executives, etc. – to invest in both these new solutions themselves and, when needed, in necessary human resources and/or equipment.

 

StrokEnomics department
Stryker’s Neurovascular division

CASE

8:00:00 am It is 2:20 am and the patient arrives in the angio suite 9.5 hours after the start of a stroke presenting with a complete occlusion of t...

CASE

6:10:00 pm A wake-up stroke in a young woman with a distal occlusion: how can we make the right decision that is of value for the patient?

INTERVIEW

New Technologies for Stroke Treatment

INTERVIEW

Long Term Results for the Treatment of Intracranial Aneurysms With the Surpass Evolve Flow Diverter: a Multicenter Experience

CASE

8:40:00 am Post Vaccination Venous Stroke